How Kind Patches Limited Sold Hope in a Yellow Package and Left Buyers Empty

The Promise on the Package

The front of the Kind Patches “Dopamine Patches” packaging uses the largest, boldest text to declare one thing: “Dopamine Patches.” Beneath that, in smaller font, the product claims to contain “30 Mental Wellness Patches” that “Support Dopamine and Serotonin Production” and provide “Mood Support and Positivity.”

The packaging is bright yellow. The marketing is relentless. The website features a banner with a ball-and-stick molecular model—purportedly representing the dopamine chemical compound—bonded together by smiley faces. The tagline: “Support Your Mood. Feel More You.”

On Instagram, the company posted on April 16, 2025: “Think of dopamine as your brain’s feel-good messenger—it plays a big role in your mood, motivation, and focus. When your dopamine levels are low, everything can feel a bit… off. That’s where our patch comes in.”

The problem is simple and devastating: the patches contain no dopamine whatsoever.

According to the complaint filed in Case No. 1:26-cv-01466-MAD-DJS, the ingredient list on the back of the package—in minuscule font—reveals what’s actually inside: mucuna pruriens extract (12mg), 5-HTP (5mg), lion’s mane mushroom extract (4.5mg), and rhodiola extract (3.5mg). These are herbal supplements, not neurotransmitters. They are not dopamine. They do not function as dopamine. And, critically, they cannot deliver the same neurological benefits as dopamine or a dopamine agonist when applied to the skin.

“That they call them dopamine patches is complete false advertising, which is, I think, a very unfair thing to consumers.” — Ellen Walker, PhD, Chair of Pharmaceutical Sciences, Temple University School of Pharmacy

The Science They Ignored

Dopamine is a neurotransmitter—a chemical messenger created in the brain and gut—responsible for regulating mood, movement, motivation, sleep, memory, concentration, and arousal. Low dopamine levels are linked to depression, lack of focus, anxiety, and neurological conditions including ADHD, Parkinson’s disease, and restless leg syndrome (RLS).

FDA-approved prescription medications exist to treat these conditions. Ritalin (methylphenidate) increases dopamine levels in the brain to treat ADHD. Neupro (rotigotine) is a transdermal patch that delivers a dopamine agonist—a chemical compound that mimics dopamine by stimulating dopamine receptors—to treat Parkinson’s disease and RLS.

These are pharmaceutical-grade formulations. They undergo years of development to achieve consistent, measurable transdermal delivery. Rotigotine patches use advanced penetration enhancers and specialized encapsulation technologies to cross the skin barrier.

Kind Patches’ herbal ingredients do not.

As reported in a GlobeNewswire article cited in the complaint, “Scientific research shows that the skin acts as a strong barrier designed to prevent the entry of most external substances. Effective transdermal delivery of therapeutic compounds typically requires advanced pharmaceutical formulation techniques. Herbal wellness patches containing botanical ingredients face different scientific challenges, and published research does not currently demonstrate reliable transdermal delivery of many plant compounds at therapeutic levels.”

Niousha Nader, PharmD, a board-certified critical care pharmacist and clinical consultant, explained to SELF magazine that although the patches are named after dopamine, “the patches themselves do not actually contain dopamine, but rather, vitamins and other nutrients.”

Psychiatrist Nissa Keyashian, MD, stated in an Everyday Health article: “Although limited data suggest some of the ingredients in these products may slightly help mood and cognitive symptoms, there is no strong evidence that they are effective and safe medications for ADHD.”

The complaint further notes that six of the seven clinical trials submitted by Kind Patches to the UK’s Advertising Standards Authority involved individual ingredients administered orally—not transdermally—and in quantities exceeding the amounts found in the patches. One trial had no results and was not considered.

The ASA concluded: “Considering the evidence in its entirety, we concluded that the claims has not been substantiated and the ads were misleading.”

The Regulatory Verdict Nobody Heard

On February 4, 2026, the Advertising Standards Authority (ASA)—the United Kingdom’s independent regulator of media advertising—issued a formal ruling prohibiting Kind Patches Limited from publishing a paid Facebook advertisement that made unsubstantiated health claims about the Dopamine Patches.

The ad stated: “Struggling to stay focused or feeling mentally drained? The Dopamine patch is now available… to support your emotional wellbeing.” It further claimed the patches “Supports a balanced mood,” “Helps maintain daily mental clarity,” and “Designed to reduce everyday stress.”

The ASA found that consumers would likely interpret these claims to mean the product could help with focus, mood, stress, motivation, and overall mental and emotional well-being by increasing dopamine in the body.

The regulator reviewed the evidence Kind Patches submitted in defense of its claims. The ASA found it insufficient. The ruling states: “Six of the seven clinical trials involved individual ingredients found in the Dopamine patch being administered orally, not through the skin, and in quantities that exceeded the amount found in Kind Patches’ product. One clinical trial had no results and was not considered.”

The ASA ordered Kind Patches to stop publishing the ad and prohibited the company from “stating or implying that their products had health benefits without holding adequate substantiation.”

This ruling was issued five months before the US class action lawsuit was filed. It was publicly available. It was specific. It was damning.

Kind Patches continued selling the product in the United States.

The Market They Exploited

The complaint outlines the economic and social conditions that created a target-rich environment for deceptive wellness marketing:

• Approximately 59% of US adults are worried about affording prescription medications.
• Approximately 43% of adults have failed to take medication as prescribed due to costs.
• Diagnosed and undiagnosed neurological conditions like ADHD are prevalent among adults and children.
• Growing consumer fascination with holistic alternatives to synthetic drugs has surged due to limited healthcare access, increased prescription drug costs, and greater transparency regarding dangerous side effects of long-term pharmaceutical use.

Kind Patches capitalized on this landscape. Since early 2025, the company has developed, distributed, marketed, and sold the Dopamine Patches online and in major retail stores including Walmart, Target, Amazon, Ulta Beauty, and CVS Pharmacy.

The complaint alleges: “Kind’s strategy to create a line of Dopamine Patches for sale in the supplement market is not accidental. Since early 2025, Kind, capitalizing on the public’s heightened intrigue for biohacks, has developed, distributed, marketed, and sold the Dopamine Patches in the online marketplace and at various retail stores, targeting health-conscious consumers who desire attaining the positive neurological benefits associated with the ‘feel good’ hormone dopamine.”

Consumers purchased the patches hoping to receive the benefits associated with dopamine without the obstacles, costs, or drawbacks of prescription medication. They were buying hope. They received herbal extracts and a $12–$32 receipt.

The Non-Financial Ledger

This is where the legal complaint becomes a registry of betrayal.

Kristen Maggi, a resident of Sharon Springs, New York, purchased one pack of Kind Dopamine Patches on December 23, 2025, for $18.00. She read the front label. She believed she was buying a transdermal patch that contained dopamine and would deliver its associated health benefits. She would not have purchased the patches had she known they contained no dopamine and would not work as advertised.

Arielle Wilbur, a resident of Hemet, California, purchased a pack on September 5, 2025, for $15.00. She read the label. She believed the product contained dopamine. She relied on that representation. She would not have made the purchase otherwise.

Laura Yeates, a resident of Sanborn, New York, purchased a pack on July 17, 2025, for $12.75. Same label. Same belief. Same reliance. Same regret.

Miranda Ackerman, a resident of Woodland, California, purchased a pack on November 4, 2025, on TikTok Shop for $31.99—the highest price paid among the named plaintiffs. She read the label. She believed she was receiving a patch that contained dopamine and its associated benefits. She would not have purchased the patches had she known the truth.

These are not outliers. The complaint includes a sample of online consumer complaints:

“I think it’s kind of misleading as they’re not patches containing dopamine. If only it was that easy right?” — Reddit

“If they aren’t patches containing dopamine it’s not ‘kind of’ misleading, it’s false advertising designed specifically to be 100% misleading.” — Reddit

“Honestly, the advertisements made the dopamine/mood patches seem like they would make me feel wonderful and happy with plenty of energy and motivation but I personally feel absolutely nothing… they are worthless in my opinion…” — Trustpilot

“Do not believe the reviews or commercials on this product. It does not work at all… So if you have ADHD and looking for dopamine enhancer this is not the route…” — Amazon

“I have been using the yellow dopamine patches for mood and energy and I have not felt any different I feel the same as I always do which is very disappointing because I have depression and my motivation has been so low lately I had very high hopes for these patches to then just feel the same and no change at all was very very disappointing and I really felt misled.” — Trustpilot

These are people who were struggling. They were looking for relief. They were promised a neurotransmitter. They received a sticker.

Legal Receipts

The complaint filed on July 29, 2026, in the United States District Court for the Northern District of New York asserts six causes of action:

1. Deceptive Acts and Practices under New York General Business Law § 349 (New York Class).
2. False Advertising under New York General Business Law § 350 (New York Class).
3. Unfair Competition under California Business & Professions Code § 17200 (California Class).
4. False Advertising under California Business & Professions Code § 17500 (California Class).
5. Consumers Legal Remedies Act Violation under California Civil Code § 1750 (California Class).
6. Unjust Enrichment (Nationwide Class).

The complaint defines three proposed classes:

• Nationwide Class: All persons in the United States who, during the applicable statute of limitations, purchased Kind Dopamine Patches.
• New York Class: All persons in New York who, during the applicable statute of limitations, purchased Kind Dopamine Patches.
• California Class: All persons in California who, during the applicable statute of limitations, purchased Kind Dopamine Patches.

The plaintiffs are represented by KalielGold PLLC. The complaint alleges that Defendant’s advertising claim that the Dopamine Patches contained dopamine “was not only a material factor, but the only factor in influencing Plaintiffs’ decisions to purchase and use the Dopamine Patches.”

Paragraph 51 of the complaint states: “In fact, Defendant has admitted on its website, buried in fine print where consumers are not likely to see, that its Dopamine Patches do not contain dopamine.”

The company knew. The company disclosed. The company buried the disclosure. The company kept selling.

Societal Impact Mapping

Public Health

The false marketing of ineffective mental health products to vulnerable consumers is not a victimless business model. It delays or prevents individuals from seeking effective treatment. It normalizes the idea that neurological conditions can be managed with unregulated herbal stickers. It preys on desperation.

The complaint notes that consumers purchased Kind’s Dopamine Patches “in hopes that they will receive the positive attributes commonly associated with dopamine without any of the aforementioned obstacles, costs, or drawbacks. In reality, however, because the Dopamine Patches do not contain ‘dopamine’ as advertised, consumers do not receive any of the promised health benefits.”

This is not a case of mild exaggeration. This is a case of labeling a product with the name of a specific neurotransmitter that is not present in the product at all.

Economic Inequality

The individuals most likely to purchase these patches are those who cannot afford prescription medications or access to healthcare. They are the 43% of adults who skip doses to save money. They are the 59% worried about affording their next refill.

Kind Patches offered them a cheaper alternative. The patches cost between $12.75 and $31.99 per pack. A month’s supply of Ritalin can cost $50–$150 without insurance. A month’s supply of Neupro patches can exceed $500 without insurance.

The economic calculation is simple for a struggling consumer: $18 for 30 patches versus $150 for a prescription. The wellness industry understands this calculation. They designed a product to exploit it.

Environmental Degradation

This case does not involve direct environmental harm, but it does involve the waste stream of fraudulent consumer products. Every pack of Dopamine Patches sold represents packaging, shipping materials, and a transdermal adhesive product that will ultimately be discarded. The environmental cost of producing and distributing a product that does not work is a hidden externality.

The “Cost of a Life” Metric

What Now?

The class action lawsuit is pending in the Northern District of New York under Case No. 1:26-cv-01466-MAD-DJS. The plaintiffs seek certification of the proposed classes, monetary damages, statutory damages, disgorgement of profits, restitution, injunctive relief, and attorneys’ fees.

If you purchased Kind Dopamine Patches (also marketed as “Mood+ Patches (Formerly Dopamine)”) at any time since early 2025, you may be a member of the proposed class.

Regulatory Watchlist

The following regulatory bodies have jurisdiction over false advertising and deceptive trade practices in the wellness and supplement industries:

• Federal Trade Commission (FTC): Enforces truth-in-advertising laws and pursues civil penalties for deceptive marketing of health products.
• Food and Drug Administration (FDA): Regulates labeling and safety claims for dietary supplements and over-the-counter health products.
• State Attorneys General: New York and California AGs have active consumer protection divisions that pursue consumer fraud cases.
• Advertising Standards Authority (ASA, UK): Already ruled Kind Patches’ advertising misleading in February 2026.

Grassroots Resistance

Consumer protection begins with consumer awareness. Share this story. Verify product claims before purchasing wellness supplements. Report false advertising to the FTC at ReportFraud.ftc.gov.

Support organizations that advocate for healthcare access and prescription drug affordability. The economic desperation that drives consumers to purchase unregulated supplements is a policy failure, not a personal one.

Demand accountability from retailers. Walmart, Target, Amazon, Ulta Beauty, and CVS Pharmacy all sold these patches. They have a responsibility to vet the products on their shelves.

If you were harmed by this product, consider contacting the plaintiffs’ attorneys at KalielGold PLLC. Class actions exist because individual consumers cannot afford to sue corporations alone. Collective action is the only viable path to restitution and reform.